A recently reported study of RTX biosimilar along with 63% concomitant ISs [mycophenolate mofetil (MMF) or methotrexate (MTX)] also revealed improvements in skin, arthritis, CRP, and stabilization in pulmonary functions after 6 months, and the results were similar between the monotherapy and concomitant IS groups [16]. The gene discussed is CRP; the disease is arthritic joint disease.